| Literature DB >> 30701058 |
Christine Kleinert1, Matthieu Blanchet1, François Gagné2, Michel Fournier1.
Abstract
Entities:
Keywords: EE2; Immunotoxicology; Phoca vitulina; RT-qPCR
Year: 2017 PMID: 30701058 PMCID: PMC6324477 DOI: 10.4081/xeno.2017.6702
Source DB: PubMed Journal: J Xenobiot ISSN: 2039-4705
Primers used for qPCR analysis. All primers are listed from 5’ to 3’.
| Gene | Description | |
|---|---|---|
| Housekeeping Gene | ||
| ß2M | Component of MHC class I molecules | F’ CTA CGT GTC AGG GTT CCA T R’ TGC TTT ACA CGG CAG CTA |
| Genes of Interest | ||
| AHR | Regulator of cytochrome P450 | F’ ATA CAG AGT TGG ACC GTT TG R’ AAG AAG CTC TTG GCT CTT A |
| CD9 | Regulator of cell development, activation, growth and motility | F’ TCT TTG GCT TCC TCT TGG T R’ TTG GAC TTC AGC TTG TTG TA |
| HSP70 | Aids with protein folding under heat or chemical stress | F’ GCA ACG TGC TCA TCT TTG A R’ AGC CTG TTG TCA AAG TCC T |
| IFNγ | Cytokine; activates macrophages; induces MHC class II expression | F’ CAA GGC GAT AAA TGA ACT CA R’ CGG CCT CGA AAC AGA TTC |
| LYN1 | Key enzyme in regulation of cell activation in hematopoietic cells | F’ CAA GGG AAG GTG CCA AAT T R’ GAC CAT ACA TCA GAC TTA ATC G |
| MAPKK3 | Phosphorylates mitogen-activated protein kinase (MAPK) | F’ TTG GTG GAT TCT GTA GCC A R’ AAG CCC ACA CAT CAG ACT T |
| SLAM | Surface receptor of activated T and B cells; enhances proliferation and IFNγ production | F’ CAT GAC CCT GGA GGA GAA R’ CAA GCT GCA GTT CCC ATT |
| TGFß1 | Cytokine involved in cell growth, proliferation, differentiation and apoptosis | F’ ACA CCA ACT ACT GCT TCA G R’ GCA GAA GTT GGC GTG GTA |
ß2M=beta-2 microglobulin; AHR=aryl hydrocarbon receptor; CD9=Cluster of differentiation 9; HSP70=70 kDa heat shock protein; IFNγ=interferon gamma; LYN1=Lck/Yes novel tyrosine kinase; MAPKK3=mitogenactivated protein kinase kinase; SLAM=signaling lymphocytic activation molecule; TGFß1=transforming growth factor beta 1
Spearman correlation coefficient hemi-matrix for inter-relationships of genes of interest. Significant correlations (p < 0.05 *, p < 0.01 **, p < 0.001 ***, p < 0.0001 ****) are in bold.
| AHR | CD9 | HSP70 | IFNg | LYN1 | MAPKK3 | SLAM | TGFb1 | ||
|---|---|---|---|---|---|---|---|---|---|
| AHR | r | 1.000 | |||||||
| p | <0.0001 | Strength of correlation | |||||||
| CD9 | r | .335 | 1.000 | r .00 – .19 “very weak” | |||||
| p | .204 | <0.0001 | r .20 – .39 “weak” | ||||||
| r .40 – .59 “moderate | |||||||||
| HSP70 | r | .606 | -.359 | 1.000 | r .60 – .79 “strong” | ||||
| p | .015 * | .173 | <0.0001 | r .80 – 1.0 “very strong” | |||||
| IFNγ | r | .606 | -.015 | .743 | 1.000 | ||||
| p | .015 * | .961 | .0002 *** | <0.0001 | |||||
| LYN1 | r | .809 | -.462 | .379 | .326 | 1.000 | |||
| p | .0003 *** | .074 | .148 | .217 | <0.0001 | ||||
| MAPKK3 | r | .337 | -.593 | .041 | -.132 | .546 | 1.000 | ||
| p | .201 | .017 * | .880 | .619 | .031 * | <0.0001 | |||
| SLAM | r | -.483 | .350 | -.403 | -.143 | -.680 | -.568 | 1.000 | |
| p | .059 | .183 | .121 | .592 | .005 ** | .023 * | <0.0001 | ||
| TGFß1 | r | .236 | .003 | -.336 | -.339 | .483 | .519 | -.158 | 1.000 |
| p | .377 | .994 | .200 | .196 | .060 | .041 * | .549 | <0.0001 |
Figure 1.(A) Fold change in gene expression after 24 h exposure to 0 (NC) and 25 mg/L EE2 as measured by qPCR. A fold change of 1 indicated no change in comparison to the reference gene ß2M. (B) Dose-response gene expression changes of HSP70 mRNA after 24 h exposure to EE2. (C) Viability of the 11B7501 B lymphoma cell line after 24 h exposure to EE2 and EE2 + LPS. Results are expressed as Mean ± SD. (* p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001). Abbreviations: EE2=17α-ethinyl estradiol; LPS=lipopolysaccharide; ßACT=beta actin; YWHAZ=14-3-3 protein zeta/delta; AHR=aryl hydrocarbon receptor; CD9=Cluster of differentiation 9; HSP70=70 kDa heat shock protein; IFNγ=interferon gamma; LYN1=Lck/Yes novel tyrosine kinase; MAPKK3=mitogenactivated protein kinase kinase; SLAM=signaling lymphocytic activation molecule; TGFß1=transforming growth factor beta 1.
Summary of significant gene expression changes in the 11B7501 B lymphoma cell line. Up- or downregulation is described as the percentage of expression relative to the negative controls of ß2M. The ß2M negative control (-EE2/-LPS) was used to normalize genes exposed to EE2 only, whereas the ß2M negative control (-EE2/+LPS) was used to normalize genes exposed to EE2 and LPS.
| Genes | 25 000 μg/L EE2 | 25 000 μg/L EE2 + 5 μg/mL LPS |
|---|---|---|
| AHR | ⬇ 81±12 % | ⬆ 120±13 % |
| CD9 | ⬇ 59±7 % | |
| HSP70 | ⬆ 191±36 % | ⬆ 228±80 % |
| IFNγ | ⬆ 141±13 % | |
| LYN1 | ⬇ 63±14 % | ⬆ 142±17 % |
| MAPKK3 | ⬆ 163±48 % | |
| SLAM | ⬇ 63±29 % | |
| TGFß1 | ⬇ 62±15 % |
EE2=17α-ethinyl estradiol; LPS=lipopolysaccharide; AHR=aryl hydrocarbon receptor; CD9=Cluster of differentiation 9; HSP70=70 kDa heat shock protein; IFNγ=interferon gamma; LYN1=Lck/Yes novel tyrosine kinase; MAPKK3=mitogen-activated protein kinase kinase; SLAM=signaling lymphocytic activation molecule; TGFß1=transforming growth factor beta 1.